CLINICAL TRIALS PROFILE FOR CRN00808
✉ Email this page to a colleague
Clinical Trials for CRN00808
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT03276858 ↗ | Single and Multiple-Ascending Dose Study of CRN00808 in Healthy Volunteers | Completed | Crinetics Pharmaceuticals Inc. | Phase 1 | This single-center study will be conducted in 3 phases: a single-ascending dose phase (up to 8 cohorts, 8 subjects/cohort), a multiple-dose phase (up to 5 cohorts, 9 subjects/cohort), and a midazolam drug-drug interaction phase (one cohort of 8 subjects). |
| NCT03789656 ↗ | An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge) | Completed | Crinetics Pharmaceuticals Inc. | Phase 2 | An open label exploratory study designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are treated with somatostatin analogue (SSA) based treatment regimens. |
| NCT03792555 ↗ | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Evolve) | Completed | Crinetics Pharmaceuticals Inc. | Phase 2 | A Phase 2 double-blind, placebo-controlled, randomized withdrawal study is designed to evaluate the safety, efficacy, and pharmacokinetics of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly that are responders to octreotide LAR or lanreotide depot. |
| NCT04246749 ↗ | Mass Balance and Pharmacokinetics of [14C]-CRN00808 in Healthy Volunteers | Completed | Crinetics Pharmaceuticals Inc. | Phase 1 | A phase 1 healthy volunteer study to assess the mass balance, elimination, and metabolic profile of CRN00808. The study will be conducted in 2 parts: Part A, to characterize the absorption, distribution, metabolism, excretion, and mass balance of orally administered radio-labeled CRN00808; Part B, to determine the absolute bioavailability of CRN00808 administered using CRN00808 and radio-labeled CRN00808 as intravenous and oral forms. |
| NCT04261712 ↗ | A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) | Enrolling by invitation | Crinetics Pharmaceuticals Inc. | Phase 2 | A phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly. |
| NCT04837040 ↗ | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly | Recruiting | Crinetics Pharmaceuticals Inc. | Phase 3 | A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly previously treated with somatostatin receptor ligand (SRL) based treatment regimens. |
| NCT05192382 ↗ | A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2) | Recruiting | Crinetics Pharmaceuticals Inc. | Phase 3 | A randomized, placebo-controlled study designed to evaluate the safety and efficacy of paltusotine (formerly CRN00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with non-pharmacologically treated acromegaly. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CRN00808
Condition Name
Clinical Trial Locations for CRN00808
Trials by Country
Clinical Trial Progress for CRN00808
Clinical Trial Phase
Clinical Trial Sponsors for CRN00808
Sponsor Name
